We are live on
!
Find out more
Pictet Asset Management Portfolio holdings
AUM
$105B
1-Year Est. Return
38.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.95%
1 Year Est. Return
+38.07%
3 Year Est. Return
+113.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$94.8B
AUM Growth
-$8.26B
(-8%)
Cap. Flow
-$2.48B
Cap. Flow
% of AUM
-2.61%
Top 10 Holdings %
Top 10 Hldgs %
21.55%
Holding
2,181
New
100
Increased
1,075
Reduced
690
Closed
79
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$671M |
| 2 |
Broadcom
AVGO
|
+$416M |
| 3 |
ServiceNow
NOW
|
+$264M |
| 4 |
Arista Networks
ANET
|
+$262M |
| 5 |
Autodesk
ADSK
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$284M |
| 2 |
Microsoft
MSFT
|
+$281M |
| 3 |
Micron Technology
MU
|
+$275M |
| 4 |
Teradyne
TER
|
+$274M |
| 5 |
KLA
KLAC
|
+$243M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.64% |
| 2 | Industrials | 14.32% |
| 3 | Healthcare | 12.96% |
| 4 | Financials | 7.97% |
| 5 | Utilities | 7.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCHW
226
Charles Schwab
SCHW
$186B
| $89.9M | 0.09% |
956,500
-42,935
| -4% | -$4.21M |
|
227
Citigroup
C
$228B
| $89M | 0.09% |
784,856
-113,958
| -13% | -$13M |
|
228
Iron Mountain
IRM
$36.4B
| $88.2M | 0.09% |
864,737
-1,431,228
| -62% | -$142M |
|
229
Adobe
ADBE
$105B
| $87.5M | 0.09% |
359,796
-262,500
| -42% | -$72.7M |
|
|
TERN
230
DELISTED
Terns Pharmaceuticals
TERN
| $87.3M | 0.09% |
1,655,575
+78,459
| +5% | +$3.22M |
|
231
Bristol-Myers Squibb
BMY
$130B
| $86.9M | 0.09% |
1,432,429
-73,242
| -5% | -$4.27M |
|
232
Toronto Dominion Bank
TD
$201B
| $85.9M | 0.09% |
923,081
-19,455
| -2% | -$1.85M |
|
233
DTE Energy
DTE
$28.6B
| $85.3M | 0.09% |
583,536
-12,435
| -2% | -$1.75M |
|
234
ICICI Bank
IBN
$107B
| $85.3M | 0.09% |
3,294,052
+495,504
| +18% | +$14.5M |
|
235
Capital One
COF
$134B
| $84.9M | 0.09% |
465,375
+97,751
| +27% | +$20.4M |
|
236
Incyte
INCY
$24.5B
| $84.8M | 0.09% |
916,188
-399,478
| -30% | -$39.9M |
|
237
CME Group
CME
$93.2B
| $84.3M | 0.09% |
285,386
+77,148
| +37% | +$22.9M |
|
238
Newmont
NEM
$124B
| $83.5M | 0.09% |
772,367
+92,191
| +14% | +$10.6M |
|
239
PTC Therapeutics
PTCT
$6.15B
| $80.1M | 0.08% |
1,183,720
+204,763
| +21% | +$14.5M |
|
240
Cognizant
CTSH
$26.4B
| $79.7M | 0.08% |
1,298,864
-154,297
| -11% | -$11M |
|
241
Arrowhead Research
ARWR
$12.6B
| $79.6M | 0.08% |
1,273,266
+244,530
| +24% | +$15.5M |
|
242
Amphenol
APH
$206B
| $79.5M | 0.08% |
629,096
+89,454
| +17% | +$12.6M |
|
243
Neurocrine Biosciences
NBIX
$16.5B
| $78.9M | 0.08% |
602,643
-174,291
| -22% | -$23.1M |
|
244
Revvity
RVTY
$12.9B
| $78.6M | 0.08% |
897,343
-466,439
| -34% | -$46.2M |
|
245
Qualcomm
QCOM
$171B
| $77.8M | 0.08% |
604,150
+23,069
| +4% | +$3.37M |
|
246
Alnylam Pharmaceuticals
ALNY
$29.6B
| $77.5M | 0.08% |
237,920
-78,133
| -25% | -$26.6M |
|
247
Pfizer
PFE
$152B
| $76.2M | 0.08% |
2,713,383
-38,136
| -1% | -$1.02M |
|
248
HCA Healthcare
HCA
$89.1B
| $76.2M | 0.08% |
161,028
+38,961
| +32% | +$19.6M |
|
249
Celestica
CLS
$39.1B
| $75.9M | 0.08% |
269,950
+211,003
| +358% | +$61.2M |
|
250
S&P Global
SPGI
$120B
| $74.9M | 0.08% |
176,065
-29,577
| -14% | -$13.7M |
|
Similar funds
Pictet Asset Management's Q1 2026 Portfolio in Review
As of Q1 2026, Pictet Asset Management held 2,181 positions worth $94.8B, down 8% from $103B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Pictet Asset Management's Q1 2026 filing shows 100 new, 1,075 increased, 690 reduced and 79 closed positions. Its largest new stake was AstraZeneca: 3,481,864 shares worth $675M. The largest sale was Lam Research, an estimated $284M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 35% a quarter earlier, followed by Industrials and Healthcare.
- Pictet Asset Management's largest Q1 2026 buy was AstraZeneca: 3,481,864 shares worth $675M.
- Pictet Asset Management added most to Broadcom in Q1 2026, an estimated $416M increase.
- Pictet Asset Management's biggest Q1 2026 reduction was Lam Research, cutting an estimated $284M.
- Pictet Asset Management fully exited CyberArk in Q1 2026, selling an estimated $104M.
- Pictet Asset Management's ten largest holdings make up 22% of its $94.8B portfolio in Q1 2026.
- Pictet Asset Management opened 100 new positions and closed 79 in Q1 2026.
- Pictet Asset Management's portfolio value fell 8% quarter-over-quarter to $94.8B.
Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.